 | • レポートコード：MRC2-11QY08117 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は好中球エラスターゼ阻害剤のグローバル市場について調査・分析したレポートです。種類別（Brevenal、CHF-6333、Dociparstat Sodium、KRP-109、POL-6014、その他）市場規模、用途別（呼吸器系、気管支拡張症、急性骨髄性白血病、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別好中球エラスターゼ阻害剤の競争状況、市場シェア ・世界の好中球エラスターゼ阻害剤市場：種類別市場規模 2015年-2020年（Brevenal、CHF-6333、Dociparstat Sodium、KRP-109、POL-6014、その他） ・世界の好中球エラスターゼ阻害剤市場：種類別市場規模予測 2021年-2026年（Brevenal、CHF-6333、Dociparstat Sodium、KRP-109、POL-6014、その他） ・世界の好中球エラスターゼ阻害剤市場：用途別市場規模 2015年-2020年（呼吸器系、気管支拡張症、急性骨髄性白血病、その他） ・世界の好中球エラスターゼ阻害剤市場：用途別市場規模予測 2021年-2026年（呼吸器系、気管支拡張症、急性骨髄性白血病、その他） ・北米の好中球エラスターゼ阻害剤市場分析：米国、カナダ ・ヨーロッパの好中球エラスターゼ阻害剤市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの好中球エラスターゼ阻害剤市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の好中球エラスターゼ阻害剤市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの好中球エラスターゼ阻害剤市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：AstraZeneca Plc、Cantex Pharmaceuticals Inc、Chiesi Farmaceutici SpA、Kyorin Pharmaceutical Co Ltd、Polyphor Ltd ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Neutrophil Elastase Inhibitator Market
The global Neutrophil Elastase Inhibitator market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Neutrophil Elastase Inhibitator Scope and Market Size
Neutrophil Elastase Inhibitator market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Neutrophil Elastase Inhibitator market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Neutrophil Elastase Inhibitator market is segmented into
Brevenal
CHF-6333
Dociparstat Sodium
KRP-109
POL-6014
Others
Segment by Application, the Neutrophil Elastase Inhibitator market is segmented into
Respiratory
Bronchiectasis
Acute Myelocytic Leukemia
Others
Regional and Country-level Analysis
The Neutrophil Elastase Inhibitator market is analysed and market size information is provided by regions (countries).
The key regions covered in the Neutrophil Elastase Inhibitator market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Neutrophil Elastase Inhibitator Market Share Analysis
Neutrophil Elastase Inhibitator market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Neutrophil Elastase Inhibitator business, the date to enter into the Neutrophil Elastase Inhibitator market, Neutrophil Elastase Inhibitator product introduction, recent developments, etc.
The major vendors covered:
AstraZeneca Plc
Cantex Pharmaceuticals Inc
Chiesi Farmaceutici SpA
Kyorin Pharmaceutical Co Ltd
Polyphor Ltd
…
1 Study Coverage
1.1 Neutrophil Elastase Inhibitator Product Introduction
1.2 Market Segments
1.3 Key Neutrophil Elastase Inhibitator Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Neutrophil Elastase Inhibitator Market Size Growth Rate by Type
1.4.2 Brevenal
1.4.3 CHF-6333
1.4.4 Dociparstat Sodium
1.4.5 KRP-109
1.4.6 POL-6014
1.4.7 Others
1.5 Market by Application
1.5.1 Global Neutrophil Elastase Inhibitator Market Size Growth Rate by Application
1.5.2 Respiratory
1.5.3 Bronchiectasis
1.5.4 Acute Myelocytic Leukemia
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Neutrophil Elastase Inhibitator Market Size, Estimates and Forecasts
2.1.1 Global Neutrophil Elastase Inhibitator Revenue 2015-2026
2.1.2 Global Neutrophil Elastase Inhibitator Sales 2015-2026
2.2 Global Neutrophil Elastase Inhibitator, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Neutrophil Elastase Inhibitator Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Neutrophil Elastase Inhibitator Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Neutrophil Elastase Inhibitator Competitor Landscape by Players
3.1 Neutrophil Elastase Inhibitator Sales by Manufacturers
3.1.1 Neutrophil Elastase Inhibitator Sales by Manufacturers (2015-2020)
3.1.2 Neutrophil Elastase Inhibitator Sales Market Share by Manufacturers (2015-2020)
3.2 Neutrophil Elastase Inhibitator Revenue by Manufacturers
3.2.1 Neutrophil Elastase Inhibitator Revenue by Manufacturers (2015-2020)
3.2.2 Neutrophil Elastase Inhibitator Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Neutrophil Elastase Inhibitator Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Neutrophil Elastase Inhibitator Revenue in 2019
3.2.5 Global Neutrophil Elastase Inhibitator Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Neutrophil Elastase Inhibitator Price by Manufacturers
3.4 Neutrophil Elastase Inhibitator Manufacturing Base Distribution, Product Types
3.4.1 Neutrophil Elastase Inhibitator Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Neutrophil Elastase Inhibitator Product Type
3.4.3 Date of International Manufacturers Enter into Neutrophil Elastase Inhibitator Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Neutrophil Elastase Inhibitator Market Size by Type (2015-2020)
4.1.1 Global Neutrophil Elastase Inhibitator Sales by Type (2015-2020)
4.1.2 Global Neutrophil Elastase Inhibitator Revenue by Type (2015-2020)
4.1.3 Neutrophil Elastase Inhibitator Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Neutrophil Elastase Inhibitator Market Size Forecast by Type (2021-2026)
4.2.1 Global Neutrophil Elastase Inhibitator Sales Forecast by Type (2021-2026)
4.2.2 Global Neutrophil Elastase Inhibitator Revenue Forecast by Type (2021-2026)
4.2.3 Neutrophil Elastase Inhibitator Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Neutrophil Elastase Inhibitator Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Neutrophil Elastase Inhibitator Market Size by Application (2015-2020)
5.1.1 Global Neutrophil Elastase Inhibitator Sales by Application (2015-2020)
5.1.2 Global Neutrophil Elastase Inhibitator Revenue by Application (2015-2020)
5.1.3 Neutrophil Elastase Inhibitator Price by Application (2015-2020)
5.2 Neutrophil Elastase Inhibitator Market Size Forecast by Application (2021-2026)
5.2.1 Global Neutrophil Elastase Inhibitator Sales Forecast by Application (2021-2026)
5.2.2 Global Neutrophil Elastase Inhibitator Revenue Forecast by Application (2021-2026)
5.2.3 Global Neutrophil Elastase Inhibitator Price Forecast by Application (2021-2026)
6 North America
6.1 North America Neutrophil Elastase Inhibitator by Country
6.1.1 North America Neutrophil Elastase Inhibitator Sales by Country
6.1.2 North America Neutrophil Elastase Inhibitator Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Neutrophil Elastase Inhibitator Market Facts & Figures by Type
6.3 North America Neutrophil Elastase Inhibitator Market Facts & Figures by Application
7 Europe
7.1 Europe Neutrophil Elastase Inhibitator by Country
7.1.1 Europe Neutrophil Elastase Inhibitator Sales by Country
7.1.2 Europe Neutrophil Elastase Inhibitator Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Neutrophil Elastase Inhibitator Market Facts & Figures by Type
7.3 Europe Neutrophil Elastase Inhibitator Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Neutrophil Elastase Inhibitator by Region
8.1.1 Asia Pacific Neutrophil Elastase Inhibitator Sales by Region
8.1.2 Asia Pacific Neutrophil Elastase Inhibitator Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Neutrophil Elastase Inhibitator Market Facts & Figures by Type
8.3 Asia Pacific Neutrophil Elastase Inhibitator Market Facts & Figures by Application
9 Latin America
9.1 Latin America Neutrophil Elastase Inhibitator by Country
9.1.1 Latin America Neutrophil Elastase Inhibitator Sales by Country
9.1.2 Latin America Neutrophil Elastase Inhibitator Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Neutrophil Elastase Inhibitator Market Facts & Figures by Type
9.3 Central & South America Neutrophil Elastase Inhibitator Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Neutrophil Elastase Inhibitator by Country
10.1.1 Middle East and Africa Neutrophil Elastase Inhibitator Sales by Country
10.1.2 Middle East and Africa Neutrophil Elastase Inhibitator Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Neutrophil Elastase Inhibitator Market Facts & Figures by Type
10.3 Middle East and Africa Neutrophil Elastase Inhibitator Market Facts & Figures by Application
11 Company Profiles
11.1 AstraZeneca Plc
11.1.1 AstraZeneca Plc Corporation Information
11.1.2 AstraZeneca Plc Description and Business Overview
11.1.3 AstraZeneca Plc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AstraZeneca Plc Neutrophil Elastase Inhibitator Products Offered
11.1.5 AstraZeneca Plc Related Developments
11.2 Cantex Pharmaceuticals Inc
11.2.1 Cantex Pharmaceuticals Inc Corporation Information
11.2.2 Cantex Pharmaceuticals Inc Description and Business Overview
11.2.3 Cantex Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Cantex Pharmaceuticals Inc Neutrophil Elastase Inhibitator Products Offered
11.2.5 Cantex Pharmaceuticals Inc Related Developments
11.3 Chiesi Farmaceutici SpA
11.3.1 Chiesi Farmaceutici SpA Corporation Information
11.3.2 Chiesi Farmaceutici SpA Description and Business Overview
11.3.3 Chiesi Farmaceutici SpA Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Chiesi Farmaceutici SpA Neutrophil Elastase Inhibitator Products Offered
11.3.5 Chiesi Farmaceutici SpA Related Developments
11.4 Kyorin Pharmaceutical Co Ltd
11.4.1 Kyorin Pharmaceutical Co Ltd Corporation Information
11.4.2 Kyorin Pharmaceutical Co Ltd Description and Business Overview
11.4.3 Kyorin Pharmaceutical Co Ltd Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Kyorin Pharmaceutical Co Ltd Neutrophil Elastase Inhibitator Products Offered
11.4.5 Kyorin Pharmaceutical Co Ltd Related Developments
11.5 Polyphor Ltd
11.5.1 Polyphor Ltd Corporation Information
11.5.2 Polyphor Ltd Description and Business Overview
11.5.3 Polyphor Ltd Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Polyphor Ltd Neutrophil Elastase Inhibitator Products Offered
11.5.5 Polyphor Ltd Related Developments
11.1 AstraZeneca Plc
11.1.1 AstraZeneca Plc Corporation Information
11.1.2 AstraZeneca Plc Description and Business Overview
11.1.3 AstraZeneca Plc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AstraZeneca Plc Neutrophil Elastase Inhibitator Products Offered
11.1.5 AstraZeneca Plc Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Neutrophil Elastase Inhibitator Market Estimates and Projections by Region
12.1.1 Global Neutrophil Elastase Inhibitator Sales Forecast by Regions 2021-2026
12.1.2 Global Neutrophil Elastase Inhibitator Revenue Forecast by Regions 2021-2026
12.2 North America Neutrophil Elastase Inhibitator Market Size Forecast (2021-2026)
12.2.1 North America: Neutrophil Elastase Inhibitator Sales Forecast (2021-2026)
12.2.2 North America: Neutrophil Elastase Inhibitator Revenue Forecast (2021-2026)
12.2.3 North America: Neutrophil Elastase Inhibitator Market Size Forecast by Country (2021-2026)
12.3 Europe Neutrophil Elastase Inhibitator Market Size Forecast (2021-2026)
12.3.1 Europe: Neutrophil Elastase Inhibitator Sales Forecast (2021-2026)
12.3.2 Europe: Neutrophil Elastase Inhibitator Revenue Forecast (2021-2026)
12.3.3 Europe: Neutrophil Elastase Inhibitator Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Neutrophil Elastase Inhibitator Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Neutrophil Elastase Inhibitator Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Neutrophil Elastase Inhibitator Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Neutrophil Elastase Inhibitator Market Size Forecast by Region (2021-2026)
12.5 Latin America Neutrophil Elastase Inhibitator Market Size Forecast (2021-2026)
12.5.1 Latin America: Neutrophil Elastase Inhibitator Sales Forecast (2021-2026)
12.5.2 Latin America: Neutrophil Elastase Inhibitator Revenue Forecast (2021-2026)
12.5.3 Latin America: Neutrophil Elastase Inhibitator Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Neutrophil Elastase Inhibitator Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Neutrophil Elastase Inhibitator Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Neutrophil Elastase Inhibitator Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Neutrophil Elastase Inhibitator Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Neutrophil Elastase Inhibitator Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Neutrophil Elastase Inhibitator Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Neutrophil Elastase Inhibitator Market Segments
Table 2. Ranking of Global Top Neutrophil Elastase Inhibitator Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Neutrophil Elastase Inhibitator Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Brevenal
Table 5. Major Manufacturers of CHF-6333
Table 6. Major Manufacturers of Dociparstat Sodium
Table 7. Major Manufacturers of KRP-109
Table 8. Major Manufacturers of POL-6014
Table 9. Major Manufacturers of Others
Table 10. Global Neutrophil Elastase Inhibitator Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 11. Global Neutrophil Elastase Inhibitator Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 12. Global Neutrophil Elastase Inhibitator Sales by Regions 2015-2020 (K Pcs)
Table 13. Global Neutrophil Elastase Inhibitator Sales Market Share by Regions (2015-2020)
Table 14. Global Neutrophil Elastase Inhibitator Revenue by Regions 2015-2020 (US$ Million)
Table 15. Global Neutrophil Elastase Inhibitator Sales by Manufacturers (2015-2020) (K Pcs)
Table 16. Global Neutrophil Elastase Inhibitator Sales Share by Manufacturers (2015-2020)
Table 17. Global Neutrophil Elastase Inhibitator Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 18. Global Neutrophil Elastase Inhibitator by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neutrophil Elastase Inhibitator as of 2019)
Table 19. Neutrophil Elastase Inhibitator Revenue by Manufacturers (2015-2020) (US$ Million)
Table 20. Neutrophil Elastase Inhibitator Revenue Share by Manufacturers (2015-2020)
Table 21. Key Manufacturers Neutrophil Elastase Inhibitator Price (2015-2020) (USD/Pcs)
Table 22. Neutrophil Elastase Inhibitator Manufacturers Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Neutrophil Elastase Inhibitator Product Type
Table 24. Date of International Manufacturers Enter into Neutrophil Elastase Inhibitator Market
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Global Neutrophil Elastase Inhibitator Sales by Type (2015-2020) (K Pcs)
Table 27. Global Neutrophil Elastase Inhibitator Sales Share by Type (2015-2020)
Table 28. Global Neutrophil Elastase Inhibitator Revenue by Type (2015-2020) (US$ Million)
Table 29. Global Neutrophil Elastase Inhibitator Revenue Share by Type (2015-2020)
Table 30. Neutrophil Elastase Inhibitator Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 31. Global Neutrophil Elastase Inhibitator Sales by Application (2015-2020) (K Pcs)
Table 32. Global Neutrophil Elastase Inhibitator Sales Share by Application (2015-2020)
Table 33. North America Neutrophil Elastase Inhibitator Sales by Country (2015-2020) (K Pcs)
Table 34. North America Neutrophil Elastase Inhibitator Sales Market Share by Country (2015-2020)
Table 35. North America Neutrophil Elastase Inhibitator Revenue by Country (2015-2020) (US$ Million)
Table 36. North America Neutrophil Elastase Inhibitator Revenue Market Share by Country (2015-2020)
Table 37. North America Neutrophil Elastase Inhibitator Sales by Type (2015-2020) (K Pcs)
Table 38. North America Neutrophil Elastase Inhibitator Sales Market Share by Type (2015-2020)
Table 39. North America Neutrophil Elastase Inhibitator Sales by Application (2015-2020) (K Pcs)
Table 40. North America Neutrophil Elastase Inhibitator Sales Market Share by Application (2015-2020)
Table 41. Europe Neutrophil Elastase Inhibitator Sales by Country (2015-2020) (K Pcs)
Table 42. Europe Neutrophil Elastase Inhibitator Sales Market Share by Country (2015-2020)
Table 43. Europe Neutrophil Elastase Inhibitator Revenue by Country (2015-2020) (US$ Million)
Table 44. Europe Neutrophil Elastase Inhibitator Revenue Market Share by Country (2015-2020)
Table 45. Europe Neutrophil Elastase Inhibitator Sales by Type (2015-2020) (K Pcs)
Table 46. Europe Neutrophil Elastase Inhibitator Sales Market Share by Type (2015-2020)
Table 47. Europe Neutrophil Elastase Inhibitator Sales by Application (2015-2020) (K Pcs)
Table 48. Europe Neutrophil Elastase Inhibitator Sales Market Share by Application (2015-2020)
Table 49. Asia Pacific Neutrophil Elastase Inhibitator Sales by Region (2015-2020) (K Pcs)
Table 50. Asia Pacific Neutrophil Elastase Inhibitator Sales Market Share by Region (2015-2020)
Table 51. Asia Pacific Neutrophil Elastase Inhibitator Revenue by Region (2015-2020) (US$ Million)
Table 52. Asia Pacific Neutrophil Elastase Inhibitator Revenue Market Share by Region (2015-2020)
Table 53. Asia Pacific Neutrophil Elastase Inhibitator Sales by Type (2015-2020) (K Pcs)
Table 54. Asia Pacific Neutrophil Elastase Inhibitator Sales Market Share by Type (2015-2020)
Table 55. Asia Pacific Neutrophil Elastase Inhibitator Sales by Application (2015-2020) (K Pcs)
Table 56. Asia Pacific Neutrophil Elastase Inhibitator Sales Market Share by Application (2015-2020)
Table 57. Latin America Neutrophil Elastase Inhibitator Sales by Country (2015-2020) (K Pcs)
Table 58. Latin America Neutrophil Elastase Inhibitator Sales Market Share by Country (2015-2020)
Table 59. Latin Americaa Neutrophil Elastase Inhibitator Revenue by Country (2015-2020) (US$ Million)
Table 60. Latin America Neutrophil Elastase Inhibitator Revenue Market Share by Country (2015-2020)
Table 61. Latin America Neutrophil Elastase Inhibitator Sales by Type (2015-2020) (K Pcs)
Table 62. Latin America Neutrophil Elastase Inhibitator Sales Market Share by Type (2015-2020)
Table 63. Latin America Neutrophil Elastase Inhibitator Sales by Application (2015-2020) (K Pcs)
Table 64. Latin America Neutrophil Elastase Inhibitator Sales Market Share by Application (2015-2020)
Table 65. Middle East and Africa Neutrophil Elastase Inhibitator Sales by Country (2015-2020) (K Pcs)
Table 66. Middle East and Africa Neutrophil Elastase Inhibitator Sales Market Share by Country (2015-2020)
Table 67. Middle East and Africa Neutrophil Elastase Inhibitator Revenue by Country (2015-2020) (US$ Million)
Table 68. Middle East and Africa Neutrophil Elastase Inhibitator Revenue Market Share by Country (2015-2020)
Table 69. Middle East and Africa Neutrophil Elastase Inhibitator Sales by Type (2015-2020) (K Pcs)
Table 70. Middle East and Africa Neutrophil Elastase Inhibitator Sales Market Share by Type (2015-2020)
Table 71. Middle East and Africa Neutrophil Elastase Inhibitator Sales by Application (2015-2020) (K Pcs)
Table 72. Middle East and Africa Neutrophil Elastase Inhibitator Sales Market Share by Application (2015-2020)
Table 73. AstraZeneca Plc Corporation Information
Table 74. AstraZeneca Plc Description and Major Businesses
Table 75. AstraZeneca Plc Neutrophil Elastase Inhibitator Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 76. AstraZeneca Plc Product
Table 77. AstraZeneca Plc Recent Development
Table 78. Cantex Pharmaceuticals Inc Corporation Information
Table 79. Cantex Pharmaceuticals Inc Description and Major Businesses
Table 80. Cantex Pharmaceuticals Inc Neutrophil Elastase Inhibitator Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 81. Cantex Pharmaceuticals Inc Product
Table 82. Cantex Pharmaceuticals Inc Recent Development
Table 83. Chiesi Farmaceutici SpA Corporation Information
Table 84. Chiesi Farmaceutici SpA Description and Major Businesses
Table 85. Chiesi Farmaceutici SpA Neutrophil Elastase Inhibitator Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 86. Chiesi Farmaceutici SpA Product
Table 87. Chiesi Farmaceutici SpA Recent Development
Table 88. Kyorin Pharmaceutical Co Ltd Corporation Information
Table 89. Kyorin Pharmaceutical Co Ltd Description and Major Businesses
Table 90. Kyorin Pharmaceutical Co Ltd Neutrophil Elastase Inhibitator Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 91. Kyorin Pharmaceutical Co Ltd Product
Table 92. Kyorin Pharmaceutical Co Ltd Recent Development
Table 93. Polyphor Ltd Corporation Information
Table 94. Polyphor Ltd Description and Major Businesses
Table 95. Polyphor Ltd Neutrophil Elastase Inhibitator Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 96. Polyphor Ltd Product
Table 97. Polyphor Ltd Recent Development
Table 98. Global Neutrophil Elastase Inhibitator Sales Forecast by Regions (2021-2026) (K Pcs)
Table 99. Global Neutrophil Elastase Inhibitator Sales Market Share Forecast by Regions (2021-2026)
Table 100. Global Neutrophil Elastase Inhibitator Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 101. Global Neutrophil Elastase Inhibitator Revenue Market Share Forecast by Regions (2021-2026)
Table 102. North America: Neutrophil Elastase Inhibitator Sales Forecast by Country (2021-2026) (K Pcs)
Table 103. North America: Neutrophil Elastase Inhibitator Revenue Forecast by Country (2021-2026) (US$ Million)
Table 104. Europe: Neutrophil Elastase Inhibitator Sales Forecast by Country (2021-2026) (K Pcs)
Table 105. Europe: Neutrophil Elastase Inhibitator Revenue Forecast by Country (2021-2026) (US$ Million)
Table 106. Asia Pacific: Neutrophil Elastase Inhibitator Sales Forecast by Region (2021-2026) (K Pcs)
Table 107. Asia Pacific: Neutrophil Elastase Inhibitator Revenue Forecast by Region (2021-2026) (US$ Million)
Table 108. Latin America: Neutrophil Elastase Inhibitator Sales Forecast by Country (2021-2026) (K Pcs)
Table 109. Latin America: Neutrophil Elastase Inhibitator Revenue Forecast by Country (2021-2026) (US$ Million)
Table 110. Middle East and Africa: Neutrophil Elastase Inhibitator Sales Forecast by Country (2021-2026) (K Pcs)
Table 111. Middle East and Africa: Neutrophil Elastase Inhibitator Revenue Forecast by Country (2021-2026) (US$ Million)
Table 112. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 113. Key Challenges
Table 114. Market Risks
Table 115. Main Points Interviewed from Key Neutrophil Elastase Inhibitator Players
Table 116. Neutrophil Elastase Inhibitator Customers List
Table 117. Neutrophil Elastase Inhibitator Distributors List
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. Neutrophil Elastase Inhibitator Product Picture
Figure 2. Global Neutrophil Elastase Inhibitator Sales Market Share by Type in 2020 & 2026
Figure 3. Brevenal Product Picture
Figure 4. CHF-6333 Product Picture
Figure 5. Dociparstat Sodium Product Picture
Figure 6. KRP-109 Product Picture
Figure 7. POL-6014 Product Picture
Figure 8. Others Product Picture
Figure 9. Global Neutrophil Elastase Inhibitator Sales Market Share by Application in 2020 & 2026
Figure 10. Respiratory
Figure 11. Bronchiectasis
Figure 12. Acute Myelocytic Leukemia
Figure 13. Others
Figure 14. Neutrophil Elastase Inhibitator Report Years Considered
Figure 15. Global Neutrophil Elastase Inhibitator Market Size 2015-2026 (US$ Million)
Figure 16. Global Neutrophil Elastase Inhibitator Sales 2015-2026 (K Pcs)
Figure 17. Global Neutrophil Elastase Inhibitator Market Size Market Share by Region: 2020 Versus 2026
Figure 18. Global Neutrophil Elastase Inhibitator Sales Market Share by Region (2015-2020)
Figure 19. Global Neutrophil Elastase Inhibitator Sales Market Share by Region in 2019
Figure 20. Global Neutrophil Elastase Inhibitator Revenue Market Share by Region (2015-2020)
Figure 21. Global Neutrophil Elastase Inhibitator Revenue Market Share by Region in 2019
Figure 22. Global Neutrophil Elastase Inhibitator Sales Share by Manufacturer in 2019
Figure 23. The Top 10 and 5 Players Market Share by Neutrophil Elastase Inhibitator Revenue in 2019
Figure 24. Neutrophil Elastase Inhibitator Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 25. Global Neutrophil Elastase Inhibitator Sales Market Share by Type (2015-2020)
Figure 26. Global Neutrophil Elastase Inhibitator Sales Market Share by Type in 2019
Figure 27. Global Neutrophil Elastase Inhibitator Revenue Market Share by Type (2015-2020)
Figure 28. Global Neutrophil Elastase Inhibitator Revenue Market Share by Type in 2019
Figure 29. Global Neutrophil Elastase Inhibitator Market Share by Price Range (2015-2020)
Figure 30. Global Neutrophil Elastase Inhibitator Sales Market Share by Application (2015-2020)
Figure 31. Global Neutrophil Elastase Inhibitator Sales Market Share by Application in 2019
Figure 32. Global Neutrophil Elastase Inhibitator Revenue Market Share by Application (2015-2020)
Figure 33. Global Neutrophil Elastase Inhibitator Revenue Market Share by Application in 2019
Figure 34. North America Neutrophil Elastase Inhibitator Sales Growth Rate 2015-2020 (K Pcs)
Figure 35. North America Neutrophil Elastase Inhibitator Revenue Growth Rate 2015-2020 (US$ Million)
Figure 36. North America Neutrophil Elastase Inhibitator Sales Market Share by Country in 2019
Figure 37. North America Neutrophil Elastase Inhibitator Revenue Market Share by Country in 2019
Figure 38. U.S. Neutrophil Elastase Inhibitator Sales Growth Rate (2015-2020) (K Pcs)
Figure 39. U.S. Neutrophil Elastase Inhibitator Revenue Growth Rate (2015-2020) (US$ Million)
Figure 40. Canada Neutrophil Elastase Inhibitator Sales Growth Rate (2015-2020) (K Pcs)
Figure 41. Canada Neutrophil Elastase Inhibitator Revenue Growth Rate (2015-2020) (US$ Million)
Figure 42. North America Neutrophil Elastase Inhibitator Market Share by Type in 2019
Figure 43. North America Neutrophil Elastase Inhibitator Market Share by Application in 2019
Figure 44. Europe Neutrophil Elastase Inhibitator Sales Growth Rate 2015-2020 (K Pcs)
Figure 45. Europe Neutrophil Elastase Inhibitator Revenue Growth Rate 2015-2020 (US$ Million)
Figure 46. Europe Neutrophil Elastase Inhibitator Sales Market Share by Country in 2019
Figure 47. Europe Neutrophil Elastase Inhibitator Revenue Market Share by Country in 2019
Figure 48. Germany Neutrophil Elastase Inhibitator Sales Growth Rate (2015-2020) (K Pcs)
Figure 49. Germany Neutrophil Elastase Inhibitator Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. France Neutrophil Elastase Inhibitator Sales Growth Rate (2015-2020) (K Pcs)
Figure 51. France Neutrophil Elastase Inhibitator Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. U.K. Neutrophil Elastase Inhibitator Sales Growth Rate (2015-2020) (K Pcs)
Figure 53. U.K. Neutrophil Elastase Inhibitator Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Italy Neutrophil Elastase Inhibitator Sales Growth Rate (2015-2020) (K Pcs)
Figure 55. Italy Neutrophil Elastase Inhibitator Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Russia Neutrophil Elastase Inhibitator Sales Growth Rate (2015-2020) (K Pcs)
Figure 57. Russia Neutrophil Elastase Inhibitator Revenue Growth Rate (2015-2020) (US$ Million)
Figure 58. Europe Neutrophil Elastase Inhibitator Market Share by Type in 2019
Figure 59. Europe Neutrophil Elastase Inhibitator Market Share by Application in 2019
Figure 60. Asia Pacific Neutrophil Elastase Inhibitator Sales Growth Rate 2015-2020 (K Pcs)
Figure 61. Asia Pacific Neutrophil Elastase Inhibitator Revenue Growth Rate 2015-2020 (US$ Million)
Figure 62. Asia Pacific Neutrophil Elastase Inhibitator Sales Market Share by Region in 2019
Figure 63. Asia Pacific Neutrophil Elastase Inhibitator Revenue Market Share by Region in 2019
Figure 64. China Neutrophil Elastase Inhibitator Sales Growth Rate (2015-2020) (K Pcs)
Figure 65. China Neutrophil Elastase Inhibitator Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. Japan Neutrophil Elastase Inhibitator Sales Growth Rate (2015-2020) (K Pcs)
Figure 67. Japan Neutrophil Elastase Inhibitator Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. South Korea Neutrophil Elastase Inhibitator Sales Growth Rate (2015-2020) (K Pcs)
Figure 69. South Korea Neutrophil Elastase Inhibitator Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. India Neutrophil Elastase Inhibitator Sales Growth Rate (2015-2020) (K Pcs)
Figure 71. India Neutrophil Elastase Inhibitator Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Australia Neutrophil Elastase Inhibitator Sales Growth Rate (2015-2020) (K Pcs)
Figure 73. Australia Neutrophil Elastase Inhibitator Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Taiwan Neutrophil Elastase Inhibitator Sales Growth Rate (2015-2020) (K Pcs)
Figure 75. Taiwan Neutrophil Elastase Inhibitator Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Indonesia Neutrophil Elastase Inhibitator Sales Growth Rate (2015-2020) (K Pcs)
Figure 77. Indonesia Neutrophil Elastase Inhibitator Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Thailand Neutrophil Elastase Inhibitator Sales Growth Rate (2015-2020) (K Pcs)
Figure 79. Thailand Neutrophil Elastase Inhibitator Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Malaysia Neutrophil Elastase Inhibitator Sales Growth Rate (2015-2020) (K Pcs)
Figure 81. Malaysia Neutrophil Elastase Inhibitator Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Philippines Neutrophil Elastase Inhibitator Sales Growth Rate (2015-2020) (K Pcs)
Figure 83. Philippines Neutrophil Elastase Inhibitator Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Vietnam Neutrophil Elastase Inhibitator Sales Growth Rate (2015-2020) (K Pcs)
Figure 85. Vietnam Neutrophil Elastase Inhibitator Revenue Growth Rate (2015-2020) (US$ Million)
Figure 86. Asia Pacific Neutrophil Elastase Inhibitator Market Share by Type in 2019
Figure 87. Asia Pacific Neutrophil Elastase Inhibitator Market Share by Application in 2019
Figure 88. Latin America Neutrophil Elastase Inhibitator Sales Growth Rate 2015-2020 (K Pcs)
Figure 89. Latin America Neutrophil Elastase Inhibitator Revenue Growth Rate 2015-2020 (US$ Million)
Figure 90. Latin America Neutrophil Elastase Inhibitator Sales Market Share by Country in 2019
Figure 91. Latin America Neutrophil Elastase Inhibitator Revenue Market Share by Country in 2019
Figure 92. Mexico Neutrophil Elastase Inhibitator Sales Growth Rate (2015-2020) (K Pcs)
Figure 93. Mexico Neutrophil Elastase Inhibitator Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Brazil Neutrophil Elastase Inhibitator Sales Growth Rate (2015-2020) (K Pcs)
Figure 95. Brazil Neutrophil Elastase Inhibitator Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Argentina Neutrophil Elastase Inhibitator Sales Growth Rate (2015-2020) (K Pcs)
Figure 97. Argentina Neutrophil Elastase Inhibitator Revenue Growth Rate (2015-2020) (US$ Million)
Figure 98. Latin America Neutrophil Elastase Inhibitator Market Share by Type in 2019
Figure 99. Latin America Neutrophil Elastase Inhibitator Market Share by Application in 2019
Figure 100. Middle East and Africa Neutrophil Elastase Inhibitator Sales Growth Rate 2015-2020 (K Pcs)
Figure 101. Middle East and Africa Neutrophil Elastase Inhibitator Revenue Growth Rate 2015-2020 (US$ Million)
Figure 102. Middle East and Africa Neutrophil Elastase Inhibitator Sales Market Share by Country in 2019
Figure 103. Middle East and Africa Neutrophil Elastase Inhibitator Revenue Market Share by Country in 2019
Figure 104. Turkey Neutrophil Elastase Inhibitator Sales Growth Rate (2015-2020) (K Pcs)
Figure 105. Turkey Neutrophil Elastase Inhibitator Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. Saudi Arabia Neutrophil Elastase Inhibitator Sales Growth Rate (2015-2020) (K Pcs)
Figure 107. Saudi Arabia Neutrophil Elastase Inhibitator Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. U.A.E Neutrophil Elastase Inhibitator Sales Growth Rate (2015-2020) (K Pcs)
Figure 109. U.A.E Neutrophil Elastase Inhibitator Revenue Growth Rate (2015-2020) (US$ Million)
Figure 110. Middle East and Africa Neutrophil Elastase Inhibitator Market Share by Type in 2019
Figure 111. Middle East and Africa Neutrophil Elastase Inhibitator Market Share by Application in 2019
Figure 112. North America Neutrophil Elastase Inhibitator Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 113. North America Neutrophil Elastase Inhibitator Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Europe Neutrophil Elastase Inhibitator Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 115. Europe Neutrophil Elastase Inhibitator Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Asia Pacific Neutrophil Elastase Inhibitator Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 117. Asia Pacific Neutrophil Elastase Inhibitator Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Latin America Neutrophil Elastase Inhibitator Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 119. Latin America Neutrophil Elastase Inhibitator Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Middle East and Africa Neutrophil Elastase Inhibitator Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 121. Middle East and Africa Neutrophil Elastase Inhibitator Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 122. Porter's Five Forces Analysis
Figure 123. Channels of Distribution
Figure 124. Distributors Profiles
Figure 125. Bottom-up and Top-down Approaches for This Report
Figure 126. Data Triangulation
Figure 127. Key Executives Interviewed
下気道感染症治療の世界市場（～2026年） The infection below the level of larynx is said to be lower respiratory tract infection. Many a times, lower respiratory tract infection is called pneumonia. These infection are not defined uniformly, but epidemiologically, these infections includes flu, bronchitis, bronchiolitis, and pneumonia. The…- 呼吸器疾患用吸入器の世界市場（～2026年） Respiratory disorders have always been a huge challenge for the drug manufacturers and the medical practitioners. In the last couple of decades, this respiratory disorder prevalence has increased tremendously due to some of the reasons such as air pollution, smoking, industrialization among others. …
- 呼吸ゲーティングシステムの世界市場（～2026年） Respiratory gating system is essential to the imaging diagnoses and the radiation therapy. The respiratory gating system is expected to grow over the forecast period owing to the increasing adoption of the products across the world. Market Analysis and Insights: Global Respiratory Gating System Mark…
- 気道感染症治療の世界市場（～2026年） Market Analysis and Insights: Global Respiratory Tract Infection Treatment Market The global Respiratory Tract Infection Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Respiratory Tract Infection Treatment S…
- 肺/呼吸器ドラッグデリバリーの世界市場（～2026年） Market Analysis and Insights: Global Pulmonary/ Respiratory Drug Delivery Market The global Pulmonary/ Respiratory Drug Delivery market size is projected to reach US$ 32810 million by 2026, from US$ 31560 million in 2020, at a CAGR of 3.7%% during 2021-2026. Global Pulmonary/ Respiratory Drug Delive…